Brazil regulator ANVISA approves BridgeBio Beyonttra for ATTR cardiomyopathy treatment

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00
  • ANVISA granted marketing authorization for BridgeBio acoramidis, branded BEYONTTRA, to treat wild-type or variant ATTR cardiomyopathy in adults in Brazil.
  • Approval rests on Phase 3 ATTRibute-CM data in 632 patients, showing a 42% reduction in all-cause mortality plus recurrent cardiovascular hospitalizations at Month 30 versus placebo.
  • Commercial rollout in Brazil expected to start in 2H 2026 via Biopas, part of Swixx BioPharma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060730PRIMZONEFULLFEED9713423) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.